Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Journal of Hematology & Oncologylink.springer.com · Low evidenceUVI5008 is a reversible, non-covalent Bruton’s tyrosine kinase (BTK) epi-inhibitor developed for treating B-cell malignancies. It targets chronic lymphocytic leukemia (CLL) as a potential therapeutic option to address challenges in current small molecule inhibitor treatments.
Springer NatureJournal of Hematology & OncologyParse Score